Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period Set To Expire on January 15th

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the end of Artiva Biotherapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARTV. HC Wainwright started coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Trading Down 8.9 %

Shares of NASDAQ:ARTV opened at $9.35 on Friday. The company’s fifty day moving average is $11.34. Artiva Biotherapeutics has a 1-year low of $9.30 and a 1-year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, sell-side analysts forecast that Artiva Biotherapeutics will post -4.68 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $42,000. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $135,000. JPMorgan Chase & Co. bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth $166,000. Barclays PLC purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth about $304,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Artiva Biotherapeutics during the third quarter valued at about $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.